Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
NCT06136221
Recruiting
Remote healthcare monitoring for cirrhosis has shown promise in overcoming barriers to accessing specialty care, improving healthcare quality, and reducing mortality. The LiverWatch study is investigating whether a remote nutrition, physical activity, and education intervention can improve health outcomes in those with cirrhosis. In this clinical trial, individuals will be randomized to either enhanced usual care or the LiverWatch intervention. Both groups are given fitbits and asked to increase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Michigan, Ann Arbor, Michigan +1 locations
Conditions: Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity, Muscle Loss
Register for Updates
MAAT For Young Adult Cancer Survivors
NCT06150976
Recruiting
The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. Participants in this single-group pilot trial (N=9) will complete online self-report measure... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/29/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana +2 locations
Conditions: Cancer
Register for Updates
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
NCT06157151
Recruiting
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +2 locations
Conditions: Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma, Metastatic Cervical Cancer
Register for Updates
Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans
NCT06162741
Recruiting
The VA wants to understand what type of integrative and whole health approaches are helpful for Veterans. The study is comparing two primary care based mental health treatments, a mindfulness class that teaches mindfulness meditation and a problem-solving class that teaches problem-solving skills and how to build resilience, for Veterans who are experiencing symptoms of anxiety, depression, and/or PTSD. The goal of the study is to understand if the classes reduce symptoms of anxiety, depression,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Phoenix VA Health Care System, Phoenix, AZ, Phoenix, Arizona +3 locations
Conditions: Post Traumatic Stress Disorder (PTSD), Depression, Anxiety
Register for Updates
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT06184750
Recruiting
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
07/29/2025
Locations: University of Arizona Cancer Center - Prevention Research Clinic, Tucson, Arizona +10 locations
Conditions: Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Register for Updates
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
NCT06205342
Recruiting
This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/29/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Chronic Pancreatitis, Chronic Pain
Register for Updates
Weekly Isotretinoin vs Tetracycline for Moderate Acne
NCT06225570
Recruiting
In the effort to find better treatments for Moderate Acne, which often relies on long-term antibiotic use, researchers are exploring alternative options. While Isotretinoin, a Vitamin A derivative, is highly effective for severe acne, its side effects limit its use for milder cases. A recent study from our institution investigated a new approach: weekly Isotretinoin dosing. The results were promising, with acne improvement and no major side effects. This suggests that weekly Isotretinoin could b... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/29/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Acne Vulgaris
Register for Updates
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/29/2025
Locations: Gastro Care Institute, Lancaster, California +141 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438
Recruiting
Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Moores Cancer Center /ID# 267782, La Jolla, California +60 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT06237309
Recruiting
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should). The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times *... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Arensia Exploratory Medicine Clinic, Phoenix, Arizona +38 locations
Conditions: Heart Failure
Register for Updates
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
NCT06237335
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +22 locations
Conditions: Cystic Fibrosis
Register for Updates
Cannabis for Palliative Care in Cancer
NCT06266611
Recruiting
Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) ve... Read More
Gender:
ALL
Ages:
25 years and above
Trial Updated:
07/29/2025
Locations: Anschutz Health Sciences Building, Aurora, Colorado
Conditions: Sleep, Anxiety, Depression, Pain
Register for Updates